Last reviewed · How we verify
FURESTEM-RA Inj.
At a glance
| Generic name | FURESTEM-RA Inj. |
|---|---|
| Also known as | Not applicable-observational study |
| Sponsor | Kang Stem Biotech Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
- Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis (PHASE1, PHASE2)
- Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj
- Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
- Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FURESTEM-RA Inj. CI brief — competitive landscape report
- FURESTEM-RA Inj. updates RSS · CI watch RSS
- Kang Stem Biotech Co., Ltd. portfolio CI